FIN 524

Drug Profile

FIN 524

Alternative Names: FIN-524

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Finch Therapeutics
  • Developer Finch Therapeutics Group
  • Class Bacteria
  • Mechanism of Action Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammatory bowel diseases

Most Recent Events

  • 23 Oct 2017 Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group
  • 05 Apr 2017 Finch Therapeutics and Takeda Pharmaceutical enter into a global collaboration agreement to jointly develop FIN 524
  • 23 Feb 2017 FIN 524 is available for licensing as of 23 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top